摩熵化学
数据库官网
小程序
打开微信扫一扫
首页 分子通 化学资讯 化学百科 反应查询 关于我们
请输入关键词

(3aS,4S,7aR)-hexahydro-4H-furo[2,3-b]pyran-4-yl (4-nitrophenyl) carbonate | 1075209-47-0

中文名称
——
中文别名
——
英文名称
(3aS,4S,7aR)-hexahydro-4H-furo[2,3-b]pyran-4-yl (4-nitrophenyl) carbonate
英文别名
(3aS,4S,7aR)-hexahydro-2H-furo[2,3-b]pyran-4-yl-(4-nitrophenyl)carbonate;[(3aS,4S,7aR)-3,3a,4,5,6,7a-hexahydro-2H-furo[2,3-b]pyran-4-yl] (4-nitrophenyl) carbonate
(3aS,4S,7aR)-hexahydro-4H-furo[2,3-b]pyran-4-yl (4-nitrophenyl) carbonate化学式
CAS
1075209-47-0
化学式
C14H15NO7
mdl
——
分子量
309.276
InChiKey
PZVXZMVLCGWMBO-RWMBFGLXSA-N
BEILSTEIN
——
EINECS
——
  • 物化性质
  • 计算性质
  • ADMET
  • 安全信息
  • SDS
  • 制备方法与用途
  • 上下游信息
  • 反应信息
  • 文献信息
  • 表征谱图
  • 同类化合物
  • 相关功能分类
  • 相关结构分类

计算性质

  • 辛醇/水分配系数(LogP):
    2.4
  • 重原子数:
    22
  • 可旋转键数:
    4
  • 环数:
    3.0
  • sp3杂化的碳原子比例:
    0.5
  • 拓扑面积:
    99.8
  • 氢给体数:
    0
  • 氢受体数:
    7

反应信息

点击查看最新优质反应信息

文献信息

  • [EN] FUSED 6,5 BICYCLIC RING SYSTEM P2 LIGANDS, AND METHODS FOR TREATING HIV<br/>[FR] LIGANDS P2 À SYSTÈME CYCLIQUE 6,5 BICYCLIQUE FUSIONNÉ, ET PROCÉDÉS DE TRAITEMENT D'UNE INFECTION PAR LE VIH
    申请人:PURDUE RESEARCH FOUNDATION
    公开号:WO2012092168A1
    公开(公告)日:2012-07-05
    Inhibitors of HIV-1 protease and compositions containing them are described. Use of the inhibitors and compositions containing them to treat HIV, AIDS, and AIDS-related diseases is described.
    描述了HIV-1蛋白酶的抑制剂和含有它们的组合物。描述了使用这些抑制剂和含有它们的组合物来治疗HIV、艾滋病和艾滋病相关疾病。
  • Potent HIV‐1 Protease Inhibitors Containing Carboxylic and Boronic Acids: Effect on Enzyme Inhibition and Antiviral Activity and Protein‐Ligand X‐ray Structural Studies
    作者:Arun K. Ghosh、Zilei Xia、Satish Kovela、William L. Robinson、Megan E. Johnson、Daniel W. Kneller、Yuan‐Fang Wang、Manabu Aoki、Yuki Takamatsu、Irene T. Weber、Hiroaki Mitsuya
    DOI:10.1002/cmdc.201900508
    日期:2019.11.6
    We report the synthesis and biological evaluation of phenylcarboxylic acid and phenylboronic acid containing HIV-1 protease inhibitors and their functional effect on enzyme inhibition and antiviral activity in MT-2 cell lines. Inhibitors bearing bis-THF ligand as P2 ligand and phenylcarboxylic acids and carboxamide as the P2' ligands, showed very potent HIV-1 protease inhibitory activity. However, carboxylic
    我们报告了含有 HIV-1 蛋白酶抑制剂的苯羧酸和苯硼酸的合成和生物学评价及其对 MT-2 细胞系中酶抑制和抗病毒活性的功能影响。带有作为 P2 配体的双 THF 配体和作为 P2' 配体的苯羧酸和甲酰胺的抑制剂显示出非常有效的 HIV-1 蛋白酶抑制活性。然而,相对于显示良好抗病毒 IC50 值的羧酰胺衍生抑制剂,含羧酸的抑制剂显示出非常差的抗病毒活性。以双 THF 作为 P2 配体的硼酸衍生抑制剂显示出非常有效的酶抑制活性,但在相同的测定中它显示出比地瑞那韦更低的抗病毒活性。含硼酸抑制剂和 P2-Crn-THF 配体也显示出有效的酶 Ki,但显着降低了抗病毒活性。我们评估了针对一组高度耐药的 HIV-1 变体的抗病毒活性。其中一种抑制剂对 HIVDRV R P20 和 HIVDRV R P30 病毒保持良好的抗病毒活性。我们已经确定了两种与 HIV-1 蛋白酶结合的合成抑制剂的高分辨率
  • A Photochemical Route to Optically Active Hexahydro-4<i>H</i>-furopyranol, a High-Affinity P2 Ligand for HIV-1 Protease Inhibitors
    作者:Arun K. Ghosh、William L. Robinson
    DOI:10.1021/acs.joc.9b01361
    日期:2019.8.2
    We describe here the syntheses of optically pure (3aS,4S,7aR)-hexahydro-4H-furo[2,3-b]pyran-4-ol and (3aR,4R,7aS)-hexahydro-4H-furo[2,3-b]pyran-4-ol. These stereochemically defined heterocycles are important high-affinity P2 ligands for a variety of highly potent HIV-1 protease inhibitors. The key steps involve an efficient Paternò-Büchi [2 + 2] photocycloaddition, catalytic hydrogenation, acid-catalyzed
    我们在这里描述了光学纯的(3aS,4S,7aR)-六氢-4H-呋喃[2,3-b]吡喃-4-醇和(3aR,4R,7aS)-六氢-4H-呋喃[2, 3-b]吡喃-4-醇。这些立体化学定义的杂环对于各种高效的HIV-1蛋白酶抑制剂而言都是重要的高亲和力P2配体。关键步骤涉及有效的Paternò-Büchi[2 + 2]光环加成,催化氢化,酸催化的环化反应以形成外消旋配体醇,以及固定化的Amano脂肪酶PS-30的酶促拆分。获得具有高对映体纯度的旋光配体(-)-6和(+)-6。对映体(-)-6已转化为有效的HIV-1蛋白酶抑制剂3。
  • COMPOUNDS AND METHODS FOR TREATING HIV
    申请人:GHOSH Arun K.
    公开号:US20130289067A1
    公开(公告)日:2013-10-31
    Inhibitors of HIV-1 protease and compositions containing them are described. Use of the inhibitors and compositions containing them to treat HIV, AIDS, and AIDS-related diseases is described.
    本文描述了HIV-1蛋白酶抑制剂及其组合物。描述了使用这些抑制剂和组合物来治疗HIV、艾滋病和艾滋病相关疾病的方法。
  • METHODS AND COMPOSITIONS FOR TREATING HIV INFECTIONS
    申请人:Ghosh Arun K.
    公开号:US20100113582A1
    公开(公告)日:2010-05-06
    Described herein are compounds and compositions that are useful in the treatment of HIV, AIDS, and AIDS-related diseases. In addition, compounds are described herein that are capable of inhibiting the dimerization of HIV proteases.
查看更多

同类化合物

马桑宁内酯 苦毒浆果[木防已属] 苦亭 艾瑞布林中间体 艾瑞布林 甲磺酸艾日布林 木防己苦毒宁 全内酯 二氢苦毒宁 6-甲基-4-氧代-4H-呋喃并[3,2-c]吡喃-3-甲酰氯 6-(4-羟基苯基)-2,3,3-三甲基-2H-呋喃并[5,4-b]吡喃-4-酮 4H-呋喃并[2,3-c]吡喃基莫匹罗星钠 3-甲基2H-呋喃并[2,3-c]吡喃-2-酮 3,5-二甲基2H-呋喃并[2,3-c]吡喃-2-酮 2H-呋喃并[2,3-c]吡喃-2-酮 2-[(1E,3E)-己-1,3-二烯基]-2,6-二甲基-5,6-二氢呋喃并[5,4-b]吡喃-3,4-二酮 (3aS,5S,6R,9E,14R,15R,15aR)-2,3,3a,4,5,6,7,8,11,12,13,14,15,15alpha-十四氢-6,10,14-三甲基-3-亚甲基-2-氧代-5,15-环氧环十四烷并[b]呋喃-6-醇乙酸酯 (3aR,4S,7aR)-4-羟基-3,3a,4,7a-四氢呋喃并[5,4-b]吡喃-2-酮 5-hydroxymethyl-3-methyl-2H-furo[2,3-c]pyran-2-one 5-fluoromethyl-2H-furo[2,3-c]pyran-2-one 5-chloromethyl-2H-furo[2,3-c]pyran-2-one 10,11-Anhydro-5-deoxy-1,2-O-isopropylidene-9-O-(methoxymethyl)-β-L-xylo-L-ido-7-undeculofuranose-(1,4)-pyranose-(7,3) 3,7-dimethyl-2H-furo[2,3-c]pyran-2-one 4R-(3αβ,3aβ,4β,5α,6β,7aβ)hexahydro-2,2-dimethyl-4,5-bis(phenylmethoxy)-6-[(phenylmethoxy)methyl]4H-furo[2,3-b]pyran-3-ol 10,10-dimethyl-5-(methylsulfanyl)-10,11-dihydro-8H-pyrano[4',3':4,5]furo[3,2-e]tetrazolo[1,5-c]pyrimidine (R)-3-((2R,3R,5aR,7R,9aS)-3-hydroxyhexahydro-2H-2,5a-methanopyrano[3,2-e][1,4]dioxepin-7-yl)-2-methylpropanenitrile 13-methyl-8,10,12-trioxapentacyclo[5.5.2.02,6.O3,11.05,9]-13-tetradecene 2,3,4,4a,7,8-Hexahydro-6H-2-(acetoxymethyl)-3,4-diacetoxy-1,9-dioxacyclohexainden-5-one 2,3,4,4a,7,8-Hexahydro-6H-2-methoxy-1,9-dioxacyclohexainden-5-one (-)-3a-methyl-3a,4-dihydro-1H,3H-furo[3,4-c]pyran-6,6,7-tricarboxylic acid 6,6-diethyl ester 7-methyl ester (+)-8-epi-altholactone 4-(perfluorophenyl)-3-phenylhexahydro-1H-furo[3,4-c]pyran [(2R,11S,12R,14R,15R,17R,19S)-19-tert-butyldiphenylsiloxymethyl-15-methyl-13,18-dioxadispiro(2H-3,6-dihydropyran-6,5'-oxolane-2',3''-bicyclo[4.3.0]nonane)-2-yl]phenylmethoxymethane (3aS,5S,9bS)-5-methyl-3,3a-dihydro-5H-furo[3,2-c]isochromene-2,6,9-(9bH)-trione (3aR,5R,7aR)-5-(2-hydroxypropan-2-yl)-7a-methylhexahydro-2H-furo[3,2-b]pyran-2-one 2,2,3b-trimethyl-7-vinyl-3a,5,7a,8a-tetrahydro-3bH-1,3,4,8-tetracyclopenta[a]indene ethyl 4-oxo-3-phenyl-3,3a,4,6-tetrahydro-1H-furo[3,4-c]pyran-3a-carboxylate methyl (2R,2aR,4aS,7aS,7bS)-2-methoxy-6-methyl-4-oxo-5-pentyl-2a,4,4a,7b-tetrahydro-2H-1,3,7-trioxacyclopenta[cd]indene-7a-carboxylate 4-nonyl-3-phenylhexahydro-1H-furo[3,4-c]pyran 3'-(4-methoxyphenyl)-7a'-methyl-4'H,6'H-spiro[cyclohexane-1,5'-furo[2,3-b]pyran]-2'(7a'H)-one 3',7a'-dimethyl-4'H,6'H-spiro[cyclohexane-1,5'-furo[2,3-b]pyran]-2'(7a'H)-one 2-(methylsulfanyl)-5,6-dihydro-4H-furo[2,3-b]pyran 1,1-(3-dimethylamino-3-phenylpentamethylen)-3,4-dihydro-1H-2,9-dioxafluoren 7-cyclopropyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one 7-cyclopropyl-3-phenyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one 7-cyclopropyl-3-phenyl-4,5,7,7a-tetrahydro-furo[2,3-c]pyran-2-one (4'R)-6-O-(4-cyanophenyl)-1,2,3,4-tetradeoxy-4'-(2,2,3,3,4,4,5,5,6,6,7,7,8,8,9,9,9-heptadecafluorononyl)-2',3',4',5'-tetrahydro-α-D-erythro-hexopyranoso[1,2-b]furan 2,2,3,6-tetramethyl-2,3-dihydro-4H-furo[2,3-b]pyran-4-one (1aR,4aS,5R)-7-carboethoxy-5-methylethyl-tetrahydrofurano[2,3-b]3,4-dihydro-2H-pyran (3aS,4S,7aR)-ethyl 4-methyl-3,3a,4,7a-tetrahydro-2H-furo[2,3-b]pyran-6-carboxylate